___

• Aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS et al. (2010) Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry, 67:139-145.
• Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ (2012) Ketamine for depression : where do we go from here? Biol Psychiatry, 72:537-547.
• Abelaira HM, Reus GZ, Neotti MV, Quevedo J (2014) The role of mTOR in depression and antidepressant responses. Life Sci, 101:10-14.
• Argiriadou H, Himmelseher S, Papagiannopoulou, Georgiou M, Kanakoudis F, Giala M et al. (2004) Improvement of pain treatment after major abdominal surgery with intravenous S+ ketamine. Anesth Analg, 98:1413–1418.
• Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS et al. (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry, 47:351-354.
• Bez Y (2013) İki uçlu depresyonun farmakolojik tedavisinde yenilikler. Journal of Mood Disorders, 3:559-562.
• Browne CA, Lucki I (2013) Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front Pharmacol, 4:161.
• Clements JA, Nimmo WS (1981) Pharmacokinetics and analgesic effects of ketamine in man. Br J Anaesth, 53:27–30.
• Collier BB (1981) Long-term dangers of ketamine anaesthesia. Br J Anaesth, 53:552.
• Craven R (2007) Ketamine. Anaesthesia, 62:48-53
• De Gioannis A, De Leo D (2014) Oral ketamine augmentation for chronic suicidality in treatment-resistant depression. Aust N Z J Psychiatry, 48:686.
• Denk MC, Rewerts C, Holsboer F, Erhardt-Lehmann A, Turck CW (2011) Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation. Am J Psychiatry, 168:751-752.
• Diazgranados N, Ibrahim L, Brutsche N, Newberg A, Kronstein P, Khalife S et al. (2010) A randomized add-on trial of an n-methyl- d-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry, 67:793-802.
• Ebrinç S (2013) Tedaviye dirençli tek uçlu depresyonun tedavisinde yenilikler. Journal of Mood Disorders, 3:551-553.
• Flower O, Hellings S (2012) Sedation in traumatic brain injury. Emerg Med Int, 2012:637171.
• Glue P, Gulati A, Le Nedelec M, Duffull S (2011) Dose- and exposure-response to ketamine in depression. Biol Psychiatry, 70:e9- e10.
• Goforth HW, Holsinger T (2007) Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy. J ECT, 23: 23-25.
• Grant IS, Nimmo WS, Clements JA (1981) Pharmacokinetics and analgesic effects of im and oral ketamine. Br J Anaesth, 53:805– 809.
• Green SM, Li J (2000) Ketamine in adults: what emergency physicians need to know about patient selection and emergence reactions. Acad Emerg Med, 7:278-281.
• Hocking G, Cousins MJ (2003) Ketamine in chronic pain management: an evidence-based review. Anesth Analg, 97:1730-1739.
• Honey GD, Honey RA, Sharar SR, Turner DC, Pomarol-Clotet E, Kumaran D et al. (2005) Impairment of specific episodic memory processes by sub-psychotic doses of ketamine: the effects of levels of processing at encoding and of the subsequent retrieval task. Psychopharmacology (Berl), 181:445-457.
• Hoyer C, Kranaster L, Janke C, Sartorius A (2014) Impact of the anesthetic agents ketamine, etomidate, thiopental, and propofol on seizure parameters and seizure quality in electroconvulsive therapy: a retrospective study. Eur Arch Psychiatry Clin Neurosci, 264:255-261.
• Ibrahim L, Diazdranados N, Luckenbaugh DA, Machado-Vieira R, Baumann J, Mallinger AG et al. (2011) Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry, 35:1155-1159.
• Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P et al. (2012) Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo- controlled study. Neuropsychopharmacology, 37:1526-1533
• Irwin SA, Iglewicz A (2010) Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. J Palliat Med, 13:903-908.
• Katalinic N, Lai R, Somogyi A, Mitchell PB, Glue P, Loo CK (2013) Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. Aust N Z J Psychiatry, 47:710-727.
• Kollmar R, Markovic K, Thürauf N, Schmitt H, Kornhuber J (2008) Ketamine followed by memantine for the treatment of major depression. Aust N Z J Psychiatry, 42:170.
• Kudoh A, Takahira Y, Kataqai H, Takazawa T (2002) Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg, 95:114-118.
• Lahti AC, Warfel D, Michaelidis T, Weiler MA, Frey K, Taminga CA (2001) Long-term outcome of patients who receive ketamine during research. Biol Psychiatry, 49:869-875.
• Larkin GL, Beautrais AL (2011) A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol, 14:1127-1131.
• Larsen MH, Mikkelsen JD, Hay-Schmidt A, Sandi C (2010) Regulation of brain-derived neurotrophic factor in the chronic unpredictable stress rat model and the effects of chronic antidepressant treatment. J Psychiatr Res, 44:808–816.
• Lenze EJ (2003) Comorbidity of depression and anxiety in the elderly. Curr Psychiatry Rep, 5:62-67.
• Liebrenz M, Borgeat A, Leisinger R, Stohler R (2007) Intravenous ketamine therapy in a patient with a treatment-resistant major depression. Swiss Med Wkly, 137:234-236.
• Liebrenz M, Stohler R, Borgeat A (2009) Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression. World J Biol Psychiatry, 10:640-643.
• Machado-Vieira R, Salvadore G, Diazgranados N, Zarate Jr CA (2009) Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther, 123:143-150.
• Malinovsky JM, Lapage JY, Cozian A, Mussini JM, Pinaudt M, Souron R (1993) Is ketamine or its preservative responsible for neurotoxicity in rabbits? Anesthesiology, 78:109–115.
• Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, A Gray N et al. (2003) Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry, 53:707-741.
• Mathew SJ, Murrough JW, Aan het Rot M, Collins KA, Reich DL, Charney DS (2010) Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol, 13:71-82.
• Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B et al. (2012) Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs, 26:189-204
• Messer M, Haller IV, Larson P, Pattison-Crisostomo J, Gessert CE (2010) The use of a series of ketamine infusions in two patients with treatment-resistant depression. J Neuropsychiatry Clin Neurosci, 22:442-444.
• Mjellem N, Lund A, Hole K (1993) Reduction of NMDA induced behaviour after acute and chronic administration of desipramine in mice. Neuropharmacology, 32:591-595.
• Morgan CJ, Mofeez A, Bradner B, Bromley L, Curan HV (2004) Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology, 29: 208-218.
• Morgan CJ, Curran HV, Independent Scientific Committee on Drugs (2012) Ketamine use: a review. Addiction, 107:27-38
• Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM et al. (2013) Antidepressant efficacy of ketamine in treatment –resistant major depression : a two-site randomized controlled trial. Am J Psychiatry, 170:1134-1142.
• Naughton M, Clarke G, O’Leary OF, Cryan JF, Dinan TG (2014) A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. J Affect Disord, 156:24-35.
• Niemegeers P, Schrijvers D, Madani Y, Sabbe BG (2014) Remission of treatment-resistant depression with electroconvulsive therapy and ketamine. J ECT, 30(3):e31-e32.
• O'Connor RM, Finger BC, Flor PJ, Cryan JF (2010) Metabotropic glutamate receptor 7: at the interface of cognition and emotion. Eur J Pharmacol. 639:123-131.
• Okamoto N, Nakai T, Sakamoto K, Nagafusa Y, Higuchi T, Nishikawa T (2010) Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia. J ECT, 26:223-227.
• Orrego F, Villanueva S (1993) The chemical nature of the main central excitatory transmitter: a critical appraisal based upon release studies and synaptic vesicle localization. Neuroscience, 56:539-555.
• Ostroff R, Gonzales M, Sanacora G (2005) Antidepressant effect of ketamine during ECT. Am J Psychiatry, 162:1385-1386.
• Passie T, Karst M, Wiese B, Emrich HM, Schneider U (2005) Effects of different subanesthetic doses of s-ketamine on neuropsychology, psychopathology, and state of consciousness in man. Neuropsychobiology, 51:226-233.
• Paul R, Schaaf N, Padberg F, Möller HJ, Frodl T (2009) Comparison of racemic ketamine and s-ketamine in treatment-resistant major depression: report of two cases. World J Biol Psychiatry, 10:241-244.
• Peltoniemi MA, Saari TI, Hagelberg NM, Laine K, Neuvonen PJ, Olkkola KT (2012) St John's wort greatly decreases the plasma concentrations of oral S-ketamine. Fundam Clin Pharmacol, 26:743-750.
• Perry EB Jr, Cramer JA, Cho HS, Petrakis IL, Karper LP, Genovese A et al. (2007) Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology (Berl) 192:253-260.
• Pfenninger EG, Durieux ME, Himmelseher S (2002) Cognitive impairment after small-dose ketamine isomers in comparison to equianalgesic racemic ketamine in human volunteers. Anesthesiology, 96:357-366.
• Price RB, Nock MK, Charney DS, Mathew SJ (2009) Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry, 66:522-526.
• Sachs-Ericsson N, Corsentino E, Moxley J, Hames JL, Rushing NC, Sawyer K (2013) A longitudinal study of differences in late- and early-onset geriatric depression: depressive symptoms and psychosocial, cognitive, and neurological functioning. Aging Ment Health, 17:11.
• Sanacora G, Zarate CA, Krystal JH, Manji HK (2008) Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discovery, 7:426-437.
• Skolnick P, Layer RT, Popik P, Nowak G, Pauli A, Trullas R (1996) Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry, 29:23–26.
• Skolnick P, Legutko B, Li X, Bymaster FP (2001) Current perspectives on the development of non-biogenic amine-based antidepressants. Pharmacol Res, 43:411-423.
• Szymkowicz SM, Finnegan N, Dale RM (2014) Failed response to repeat intravenous ketamine infusions in geriatric patients with major depressive disorder. J Clin Psychopharmacol, 34:285-286.
• Thakurta RG, Das R, Bhattacharya AK, Saha D, Sen S, Singh OP et al. (2012) Rapid response with ketamine on suicidal cognition in resistant depression. Indian J Psychol Med, 34:170-175.
• Wang X, Chen Y, Zhou X, Liu F, Zhang T, Zhang C (2012) Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder. J ECT, 28:128-132.
• White PF, Schuttler J, Shafer A, Stanski DR, Horai Y, Trevor AJ (1985) Comparative pharmacology of the ketamine isomers: studies in volunteers. Br J Anaesth, 57: 197–203.
• Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA et al. (2006) A randomized trial of an n-methyl-d- aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry, 63:856-864.
• Zarate CA Jr, Brutsche N, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A et al. (2012) Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry, 71:939-946.
• Feride Karacer, Uz.Dr., Çukurova Üniversitesi Tıp Fakültesi Anesteziyoloji ve Reanimasyon ABD, Adana.